HSBC Holdings’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,448
| Closed | -$67.1K | – | 3166 |
|
|
2025
Q1 | $67.1K | Sell |
6,448
-9
| -0.1% | -$118 | ﹤0.01% | 2872 |
|
|
2024
Q4 | $88.4K | Sell |
6,457
-108
| -2% | -$1.91K | ﹤0.01% | 2911 |
|
|
2024
Q3 | $129K | Buy |
6,565
+1,508
| +30% | +$28.7K | ﹤0.01% | 2743 |
|
|
2024
Q2 | $95.9K | Hold |
5,057
| – | – | ﹤0.01% | 2739 |
|
|
2024
Q1 | $70.9K | Hold |
5,057
| – | – | ﹤0.01% | 2896 |
|
|
2023
Q4 | $42.1K | Hold |
5,057
| – | – | ﹤0.01% | 2660 |
|
|
2023
Q3 | $45.6K | Hold |
5,057
| – | – | ﹤0.01% | 2637 |
|
|
2023
Q2 | $43.2K | Sell |
5,057
-390
| -7% | -$4.16K | ﹤0.01% | 2492 |
|
|
2023
Q1 | $56.7K | Sell |
5,447
-1,946
| -26% | -$58.9K | ﹤0.01% | 2560 |
|
|
2022
Q4 | $245K | Buy |
7,393
+2,015
| +37% | +$97.5K | ﹤0.01% | 2676 |
|
|
2022
Q3 | $263K | Buy |
5,378
+2,521
| +88% | +$150K | ﹤0.01% | 2485 |
|
|
2022
Q2 | $162K | Buy |
2,857
+1,397
| +96% | +$88.1K | ﹤0.01% | 2929 |
|
|
2022
Q1 | $119K | Buy |
1,460
+355
| +32% | +$52.5K | ﹤0.01% | 3094 |
|
|
2021
Q4 | $227K | Buy |
+1,105
| New | +$240K | ﹤0.01% | 2969 |
|
|
2021
Q3 | – | Sell |
-1,581
| Closed | -$410K | – | 3105 |
|
|
2021
Q2 | $410K | Buy |
+1,581
| New | +$438K | ﹤0.01% | 2312 |
|
|
2020
Q4 | – | Sell |
-1,289
| Closed | -$323K | – | 3105 |
|
|
2020
Q3 | $323K | Buy |
1,289
+203
| +19% | +$63.9K | ﹤0.01% | 2205 |
|
|
2020
Q2 | $377K | Buy |
+1,086
| New | +$339K | ﹤0.01% | 2011 |
|
|
2019
Q4 | – | Sell |
-4,510
| Closed | -$1.23M | – | 3143 |
|
|
2019
Q3 | $1.23M | Sell |
4,510
-560
| -11% | -$205K | ﹤0.01% | 1840 |
|
|
2019
Q2 | $2.71M | Buy |
5,070
+459
| +10% | +$230K | 0.01% | 1398 |
|
|
2019
Q1 | $2.32M | Buy |
4,611
+1,301
| +39% | +$771K | ﹤0.01% | 1445 |
|
|
2018
Q4 | $1.63M | Sell |
3,310
-951
| -22% | -$574K | ﹤0.01% | 1576 |
|
|
2018
Q3 | $3.84M | Buy |
4,261
+494
| +13% | +$422K | 0.01% | 1229 |
|
|
2018
Q2 | $2.76M | Sell |
3,767
-6,164
| -62% | -$7.11M | ﹤0.01% | 1388 |
|
|
2018
Q1 | $15.8M | Buy |
+9,931
| New | +$12.8M | 0.02% | 643 |
|
|
2017
Q1 | – | Sell |
-1,967
| Closed | -$362K | – | 2427 |
|
|
2016
Q4 | $362K | Buy |
+1,967
| New | +$400K | ﹤0.01% | 2085 |
|
|
2015
Q3 | – | Sell |
-736
| Closed | -$138K | – | 2091 |
|
|
2015
Q2 | $138K | Buy |
736
+5
| +0.7% | +$860 | ﹤0.01% | 1888 |
|
|
2015
Q1 | $121K | Sell |
731
-50
| -6% | -$10.3K | ﹤0.01% | 1973 |
|
|
2014
Q4 | $182K | Buy |
+781
| New | +$167K | ﹤0.01% | 1712 |
|
Other funds holding NKTR
NCM
TCM
HSBC Holdings's NKTR Position: Q2 2025 in Review
HSBC Holdings sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 6,448 shares — an estimated $67.1K sold.
HSBC Holdings first reported a position in NKTR in Q4 2014 and held it in 28 quarters. The position peaked at $15.8M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.
- HSBC Holdings reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
- HSBC Holdings sold 6,448 Nektar Therapeutics shares in Q2 2025, an estimated $67.1K.
- HSBC Holdings first reported a position in Nektar Therapeutics in Q4 2014 and held it in 28 quarters.
- HSBC Holdings's Nektar Therapeutics position peaked at $15.8M in Q1 2018.
- 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.
Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.